Capturing daily fluctuations in mood and cognition can help to more accurately monitor treatment response - but is this feasible for patients with depression?
In research presented at CNS2020, we examined the feasibility of high-frequency cognitive assessments, and their relationship with daily measures of depressive symptoms and physical activity.
We caught up with Mohammad Ali Salehinejad to discuss the results of his latest publication entitled: Cognitive control dysfunction in emotion dysregulation and psychopathology of major depression (MD): Evidence from transcranial brain stimulation of the dorsolateral prefrontal cortex (DLPFC).
PhD Student Naoise Mac Giollabhui received a CANTAB Research Grant in 2018 for his project: ‘Chronic inflammation as a pathway to cognitive dysfunction in adolescents and young adults with a history of elevated depressive symptoms’. We caught up with Naoise to discuss how the grant will benefit his research.
Takeda and Cognition Kit partner to pilot wearables in patients with Major Depressive Disorder (MDD)
Takeda Pharmaceuticals U.S.A. and Cognition Kit Limited announce a collaboration to pilot the use of a specially designed app on an Apple Watch wearable to monitor and assess cognitive function in patients with Major Depressive Disorder (MDD).
Mood disorders affect 5-10% of the adult population in a given year. The most common mood disorders are major depressive disorder, dysthymia, and bipolar disorder. Here we explore the six CANTAB tests for objectively measuring cognitive function in depression.